Right-Ace

Indication :

§ Treatment of hypertension.

§ Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

· Manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

· Diabetes with at least one cardiovascular risk factor (see section 5.1).

§ Treatment of renal disease:

· Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

· Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor (see section 5.1),

· Manifest glomerular non diabetic nephropathy as defined by macroproteinuria GREATER-THAN OR EQUAL TO (8805)3 g/day (see section 5.1).

§ Treatment of symptomatic heart failure.

§ Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started> 48 hours following acute myocardial infarction.

Composition :

Each tablet contains Ramipril 5 mg.

§ Each tablet contains Ramipril 10 mg.

For a full list of excipients, see section 6.1.